Avid Bioservices Inc (CDMO): No one is placing any weight on the PII...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	85
Posts	12714
Boards Moderated	0
Alias Born	10/12/2010

biopharm

Re: Carboat post# 267395

Sunday, 06/26/2016 10:13:58 PM

Sunday, June 26, 2016 10:13:58 PM

No one is placing any weight on the PII results.

The weight has already been placed on Phase II results and now the waiting period..... probably while the quiet period becomes more and more difficult.

NCCN, AstraZeneca, Memorial Sloan Kettering, Janssen, Pfizer, Bluebird Bio...... and a dozen more but we should probably wait a bit and allow everyone to realize that PS Targeting is not going under as predicted back in Sept of 2012

How many Millions does Peregrine have at this point?

$65 Million?

$60 Million?

... and no (Absolutely NO) debt ... and now AstraZeneca paying for much of the cost of trials.

Sunny skies ahead

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!